YU37203A - Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti - Google Patents
Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonistiInfo
- Publication number
- YU37203A YU37203A YU37203A YUP37203A YU37203A YU 37203 A YU37203 A YU 37203A YU 37203 A YU37203 A YU 37203A YU P37203 A YUP37203 A YU P37203A YU 37203 A YU37203 A YU 37203A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- compounds
- antagonists
- phenylaminoimidazoline
- substituted
- phenyl ketone
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- XSDRNCZRJVKAFM-UHFFFAOYSA-N diphenylmethanone;n-phenyl-4,5-dihydro-1h-imidazol-2-amine Chemical class N1CCN=C1NC1=CC=CC=C1.C=1C=CC=CC=1C(=O)C1=CC=CC=C1 XSDRNCZRJVKAFM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 108091006335 Prostaglandin I receptors Proteins 0.000 abstract 1
- 208000026723 Urinary tract disease Diseases 0.000 abstract 1
- 208000012931 Urologic disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenja koja su uopšte modulatori receptora prosta glandina I2 (IP), naročito antagonisti receptora IP i koja su predstavljena opštom formulom (I) u kojoj su A, R1 I R2 definisani u specifikaciji i na njihove pojedinačne izomere, racemske ili neracemske smeše izomera i farmaceutski prihvatljive soli ili solvate. Ovaj pronalazak se dalje odnosi na farmaceutske smeše koje sadrže takva jedinjenja, psotupak za dobivanje takvih jedinjenja i na njihovu primenu za lečenje bolesti koje su u vezi sa bolom, zapaljenjem, bolesnim stanjima mokraćnog trakta, respiratornim bolesnim stanjima, formiranjem edema ili hipotenzivnim vaskularnim bolestima.[This invention relates to compounds which are generally prostaglandins I2 (IP) receptor modulators, particularly IP receptor antagonists, and which are represented by the general formula (I) wherein A, R1 and R2 are defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, a process for the preparation of such compounds and their use for treating diseases associated with pain, inflammation, urinary tract disease states, respiratory disease states, edema formation, or hypotensive vascular diseases.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24888800P | 2000-11-14 | 2000-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU37203A true YU37203A (sh) | 2006-05-25 |
Family
ID=22941114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU37203A YU37203A (sh) | 2000-11-14 | 2001-11-05 | Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1339694B1 (sh) |
| JP (1) | JP4108474B2 (sh) |
| KR (1) | KR100562605B1 (sh) |
| CN (1) | CN1267423C (sh) |
| AR (1) | AR035502A1 (sh) |
| AT (1) | ATE305002T1 (sh) |
| AU (1) | AU2180802A (sh) |
| BG (1) | BG107814A (sh) |
| BR (1) | BR0115291A (sh) |
| CA (1) | CA2427900A1 (sh) |
| CZ (1) | CZ20031596A3 (sh) |
| DE (1) | DE60113563T2 (sh) |
| EC (1) | ECSP034602A (sh) |
| ES (1) | ES2248413T3 (sh) |
| HU (1) | HUP0303156A3 (sh) |
| IL (1) | IL155436A0 (sh) |
| MA (1) | MA26958A1 (sh) |
| MX (1) | MXPA03004073A (sh) |
| NO (1) | NO20032142L (sh) |
| NZ (1) | NZ525330A (sh) |
| PA (1) | PA8532201A1 (sh) |
| PE (1) | PE20020602A1 (sh) |
| PL (1) | PL362549A1 (sh) |
| RU (1) | RU2284995C2 (sh) |
| SK (1) | SK7222003A3 (sh) |
| UY (1) | UY27023A1 (sh) |
| WO (1) | WO2002040453A1 (sh) |
| YU (1) | YU37203A (sh) |
| ZA (1) | ZA200303413B (sh) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171945A1 (en) * | 2003-02-14 | 2006-08-03 | Critchley Hilary Octavia D | Ip receptor antagonists for the treatment of pathological uterine conditions |
| EP1622611A1 (en) * | 2003-05-01 | 2006-02-08 | F. Hoffmann-La Roche Ag | Imidazolin-2-ylaminophenyl amides as ip antagonists |
| WO2005000247A2 (en) * | 2003-06-25 | 2005-01-06 | Smithkline Beecham Corporation | 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |
| EP1656350A2 (en) * | 2003-07-09 | 2006-05-17 | F.Hoffmann-La Roche Ag | Thiophenylaminoimidazolines as prostaglandin i2 antagonists |
| KR20080090546A (ko) * | 2006-01-27 | 2008-10-08 | 에프. 호프만-라 로슈 아게 | Ｃｎｓ 장애 치료용 2-이미다졸의 용도 |
| ATE546437T1 (de) | 2006-10-19 | 2012-03-15 | Hoffmann La Roche | Aminomethyl-4-imidazole |
| EP2086959B1 (en) | 2006-11-02 | 2011-11-16 | F. Hoffmann-La Roche AG | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
| JP2010510184A (ja) | 2006-11-16 | 2010-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | 置換４−イミダゾール類 |
| AU2007332641A1 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR) |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| RU2473545C2 (ru) | 2007-02-02 | 2013-01-27 | Ф.Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| WO2009003868A2 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| AU2008270444A1 (en) | 2007-07-03 | 2009-01-08 | F. Hoffmann-La Roche Ag | 4-imidazolines and their use as antidepressants |
| EP2183216A1 (en) | 2007-07-27 | 2010-05-12 | F. Hoffmann-Roche AG | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands |
| CN101784515A (zh) | 2007-08-03 | 2010-07-21 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物 |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| EP2513064B1 (en) | 2009-12-17 | 2018-07-04 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Compounds, compositions and methods for controlling biofilms |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| WO2014143591A1 (en) | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors |
| US9321745B2 (en) | 2013-03-12 | 2016-04-26 | Allergan, Inc. | Inhibition of neovascularization by inhibition of prostanoid IP receptors |
| US9827225B2 (en) * | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| CR20180443A (es) | 2016-03-17 | 2018-11-21 | Hoffmann La Roche | Derivado de morfolina |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889868A (en) * | 1984-12-20 | 1989-12-26 | Rorer Pharmaceutical Corporation | Bis-imidazolinoamino derivatives as antiallergy compounds |
| GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
| NZ331480A (en) * | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
-
2001
- 2001-11-05 PL PL01362549A patent/PL362549A1/xx unknown
- 2001-11-05 DE DE60113563T patent/DE60113563T2/de not_active Expired - Fee Related
- 2001-11-05 CZ CZ20031596A patent/CZ20031596A3/cs unknown
- 2001-11-05 CA CA002427900A patent/CA2427900A1/en not_active Abandoned
- 2001-11-05 MX MXPA03004073A patent/MXPA03004073A/es active IP Right Grant
- 2001-11-05 RU RU2003115426/04A patent/RU2284995C2/ru not_active IP Right Cessation
- 2001-11-05 BR BR0115291-2A patent/BR0115291A/pt not_active IP Right Cessation
- 2001-11-05 WO PCT/EP2001/012776 patent/WO2002040453A1/en active IP Right Grant
- 2001-11-05 YU YU37203A patent/YU37203A/sh unknown
- 2001-11-05 HU HU0303156A patent/HUP0303156A3/hu unknown
- 2001-11-05 IL IL15543601A patent/IL155436A0/xx unknown
- 2001-11-05 AT AT01996531T patent/ATE305002T1/de not_active IP Right Cessation
- 2001-11-05 ES ES01996531T patent/ES2248413T3/es not_active Expired - Lifetime
- 2001-11-05 AU AU2180802A patent/AU2180802A/xx not_active Withdrawn
- 2001-11-05 SK SK722-2003A patent/SK7222003A3/sk unknown
- 2001-11-05 EP EP01996531A patent/EP1339694B1/en not_active Expired - Lifetime
- 2001-11-05 KR KR1020037006504A patent/KR100562605B1/ko not_active IP Right Cessation
- 2001-11-05 NZ NZ525330A patent/NZ525330A/en unknown
- 2001-11-05 JP JP2002542781A patent/JP4108474B2/ja not_active Expired - Fee Related
- 2001-11-05 CN CNB018187471A patent/CN1267423C/zh not_active Expired - Fee Related
- 2001-11-09 PE PE2001001118A patent/PE20020602A1/es not_active Application Discontinuation
- 2001-11-13 AR ARP010105280A patent/AR035502A1/es not_active Application Discontinuation
- 2001-11-13 PA PA20018532201A patent/PA8532201A1/es unknown
- 2001-11-13 UY UY27023A patent/UY27023A1/es not_active Application Discontinuation
-
2003
- 2003-05-02 ZA ZA200303413A patent/ZA200303413B/en unknown
- 2003-05-12 MA MA27154A patent/MA26958A1/fr unknown
- 2003-05-13 NO NO20032142A patent/NO20032142L/no not_active Application Discontinuation
- 2003-05-13 EC EC2003004602A patent/ECSP034602A/es unknown
- 2003-05-14 BG BG107814A patent/BG107814A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU37203A (sh) | Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti | |
| WO2003064387A3 (en) | Substituted indoles as alpha-1 agonists | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| DE60239939D1 (de) | Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung | |
| EE05287B1 (et) | Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| YU68102A (sh) | Derivati karboksilne kiseline kao ip antagonisti | |
| CA2449874A1 (en) | New indole derivatives with 5-ht6 receptor affinity | |
| MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
| MXPA04012998A (es) | Modulares de receptores nucleares de hormonas esteroideas triciclicos. | |
| WO2007050726A3 (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| MY140835A (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| ATE301117T1 (de) | Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
| WO2002018348A3 (en) | Quinazoline derivatives as alpha-1 adrenergic antagonists | |
| YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
| DE60230424D1 (en) | Arylsulfonyl-derivate mit 5-ht 6-rezeptor-affinität | |
| CA2354606A1 (en) | Azabicycloalkane derivatives and therapeutic uses thereof | |
| MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
| MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
| AR033430A1 (es) | Derivados de alcoxicarbonilamino tetrazolil fenilo o acido alcoxicarbonilamino benzoico, su uso, un proceso para su preparacion y composiciones farmaceuticas que los comprenden | |
| CA2292921A1 (en) | Aryl carboxylic acid and tetrazole derivatives | |
| NO980333L (no) | (R)-5-brom-N-(1-etyl-4-metylheksahydro-1H-1,4-diazepin-6-yl)-2-metoksy-6-metylamino-3-pyridinkarboksamid, fremgangsmåte ved fremstilling derav og farmasöytisk sammensetning inneholdende forbindelsen | |
| AR033429A1 (es) | Derivados del acido alcoxicarbonilamino-heteroarilcarboxilico, su uso, un procedimiento para prepararlos y composiciones farmaceuticas que los comprenden |